Drugs / PEG-G-CSF
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT01923545 | Jul 2010 → May 2011 | neutropenia | Dong-A ST Co., Ltd. | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT06711523 | Jan 2025 → Jun 2026 overdue | breast neoplasm, neutropenia | Kexing Biopharm Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT01674855 | Feb 2012 → Feb 2013 | neutropenia | Dong-A ST Co., Ltd. | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT02441894 | Apr 2015 → Feb 2016 | prostate cancer | Sanofi | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT02788240 | May 2016 → Jul 2017 | liver failure | Institute of Liver and Biliary Sciences, India | Terminated | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT03045627 Comparator | Jan 2017 → Jan 2018 | acute myeloid leukemia | Shandong University | Unknown | No outcome recorded |
| Phase 2 | NCT02042391 Background | Feb 2015 → Jul 2021 | post-transplant lymphoproliferative disease | Diako Ev. Diakonie-Krankenhaus gemeinnützige GmbH | Completed | Missed primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PEG-G-CSF | “At day 3-4 of each treatment cycle either a single dose of 6 mg Peg-GCSF or repetitive doses of 5 µg/kg GCSF until recovery of WBC will be applied subcutaneously, as per...” NCT02042391 ↗ |
| Known as | Neulasta | “Single subcutaneous injection of 6 mg PEG-G-CSF injection ( Neulasta®, Amgen Europe B.V.) 24h+2h after the end of chemotherapy administration on day 1 of each chemotherapy...” NCT06711523 ↗ |
| Modality | Protein / enzyme biologic | “Pegylated granulocyte colony-stimulating factor (PEG-G-CSF )is a long-acting reagent” NCT03045627 ↗ |
| Route | Subcutaneous | “either a single dose of 6 mg Peg-GCSF or repetitive doses of 5 µg/kg GCSF until recovery of WBC will be applied subcutaneously” NCT02042391 ↗ |